Search

Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

An Employee’s Commitment to Ensuring Access to Medicines

Country Management Committee: A Message | Boehringer Ingelheim US

Click here to read a statement from Boehringer Ingelheim on the tragic events in Uvalde, TX and how BI Cares is supporting victims and families.

BI increases commitments to sustainable development

At the World Health Summit 2021, Boehringer Ingelheim announces updates to its strategic approach to sustainable development

How Simulation is Changing the Game in Biotherapeutic Drug Development

Clinical Development and Operations

Click here to find out more on how Boehringer Ingelheim is proud to offer a new 2-year Fellowship program within Clinical Operations.

Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies

Fur-ever homes: How pet shelters and fosters have met the challenge of the pandemic

Pet shelters impacted by the COVID-19 pandemic have benefitted from the Stay Home and Foster program, which connects shelter pets with foster homes.

Biopharma Contract Manufacturing

US Privacy Statement

Jardiance® (empagliflozin) Shows Reduction in CV Risk & Death | Boehringer Ingelheim US

BI & Eli Lilly & Co.’s JARDIANCE reduced risk of CV death, non-fatal heart attack or non-fatal stroke by 14%. View ISI, PI and Med Guide.

New GPP Consensus Statement Released

National Psoriasis Foundation Releases Consensus Statement on Management of Generalized Pustular Psoriasis (GPP)

Prescription Digital Therapeutics a New Frontier in Mental Health Care

Overview of the gap in treatment accessibility for people with mental health conditions like schizophrenia and the potential applications of PDTs.

Vetmedica, Inc. Opens New R&D Facility | Boehringer Ingelheim US

Find out more on the opening of Boehringer Ingelheim Vetmedica Inc's new research and development facility in Ames, Iowa.

BI & Gubra Join Forces to Identify Peptides | Boehringer Ingelheim US

BI & Gubra announce research & licensing agreement focused on the identification & validation of targets & peptide compounds for the treatment of obesity.

Interview with Michael Schmelmer

"You can work on initiatives that can improve treatment, provision, and early disease detection"", Michael Schmelmer, Member of the Board of Managing Directors

Sustainable Development - Our Commitment

Our Commitment

Poultry vaccine site in Georgia continues to reduce carbon emissions

Going carbon neutral has resulted in measurable, positive impacts. From 2021 to 2022, the Gainesville site reduced its CO2 emissions by 23 percent – nearly 700 fewer tons of CO2 emissions are released into the atmosphere

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) for Asthma | BI US

FDA approval of SPIRIVA RESPIMAT for maintenance treatment of asthma in patients 12 and older marks a new class of treatment with once-daily prescriptions.

FDA Approves SPIRIVA® RESPIMAT® (tiotropium bromide) | BI US

Read more about the FDA approval of Boehringer Ingelheim's new inhalation treatment spray for the maintenance treatment of COPD, SPIRIVA RESPIMAT.

Scam alert

Could decentralised trials transform the way we view depression?

Could decentralised trials transform the way we view depression? Dr Vikas Mohan Sharma believes this could deliver meaningful changes for patients all arround.

How Boehringer Ingelheim US Helps Injured Veterans | Boehringer Ingelheim US

Read more on how Boehringer Ingelheim supports injured veterans in making a fresh start through the use of service dogs, with the Warrior Canine Connection.

Meet the Animal Health Partnering Team

Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers